We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

EMA Green Lights Accelerated Program for RNAi Therapeutic

News   Mar 02, 2017 | Original story Alnylam

 
EMA Green Lights Accelerated Program for RNAi Therapeutic

Credit: EMA

 
 
Advertisement
 

RELATED ARTICLES

Naltrexone–Bupropion Drug Combination May Help To Treat Methamphetamine Addiction

News

Combining the injectable drug naltrexone and a commonly prescribed antidepressant called bupropion was shown to produce positive results in 13.6 percent of 403 patients treated, significantly higher than the 2.5 percent response in placebo groups, in a study published in The New England Journal of Medicine.

READ MORE

Up to 20% of Glioblastomas Could Be Fueled by Overactive Mitochondria

News

A new study has found that up to 20% of glioblastomas – an aggressive type of brain cancer – are fueled by overactive mitochondria. The study also suggests that the mitochondrial subtype and may be treatable with existing drugs or investigational therapeutics currently in clinical development.

READ MORE

RNA Factors That Help Cancer Cells Thrive May Make Good Therapeutic Targets

News

Nucleic circ2082, a circular RNA, has been shown to disrupts the microRNA assembly line in glioblastoma cancer cells, making it a potential upstream target for the treatment of cancer.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE